Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05547074
Other study ID # PSMPDAC
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 1, 2019
Est. completion date August 31, 2022

Study information

Verified date September 2022
Source Zhejiang University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The AJCC TNM staging system is the prevailing method in prognostic evaluation of pancreatic ductal adenocarcinoma (PDAC) at present , but it did not include factors such as the tumor immune microenvironment that are known to exert a profound impact on patients'clinical outcome. This study was aimed to develop a comprehensive and effective prognostic score model to predict prognosis and guide clinical management for postoperative PDAC patients.


Recruitment information / eligibility

Status Completed
Enrollment 302
Est. completion date August 31, 2022
Est. primary completion date October 30, 2020
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: 1. Pathologically confirmed PDAC 2. Achievement of surgical resection (including radical or palliative surgery) Exclusion Criteria: 1. Lost to follow-up 2. Simultaneous presence of other tumors 3. Died in three months after surgery

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
pancreatic cancer surgery
Surgical resection of pancreatic cancer,including radical or palliative surgery

Locations

Country Name City State
China First Affiliated Hospital, Medical College of Zhejiang University Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary overall survival the number of months from the date of surgery to the date of the last follow-up visit or time of death. after pancreatic cancer surgery until october 31, 2020
Secondary disease-free survival disease-free survival disease-free survival disease-free survival the number of months from the date of surgery to the date of first confirmable recurrence or death after pancreatic cancer surgery until october 31, 2020
See also
  Status Clinical Trial Phase
Terminated NCT01313416 - Gemcitabine and CT-011 for Resected Pancreatic Cancer Phase 2
Withdrawn NCT03245658 - The Effect of Cannabis in Pancreatic Cancer Phase 2
Completed NCT02973217 - Immunostimulating Interstitial Laser Thermotherapy in Pancreatic Cancer N/A
Recruiting NCT04161417 - Precision-Panc Master Protocol: Personalising Treatment for Pancreatic Cancer N/A
Recruiting NCT04151277 - PRIMUS 001: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer Phase 2
Terminated NCT03187587 - Percutaneous Immunostimulating Interstitial Laser Thermotherapy in Pancreatic Cancer N/A
Terminated NCT04176952 - PRIMUS002: Looking at 2 Neo-adjuvant Treatment Regimens for Resectable and Borderline Resectable Pancreatic Cancer Phase 2
Recruiting NCT05669482 - Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer Phase 1/Phase 2
Completed NCT03535727 - A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer Phase 1/Phase 2
Recruiting NCT04566614 - Preventing Viral Pandemic Associated Risk of Cancer Death Using Less Invasive Diagnostic Tests- Liquid Biopsies
Completed NCT06118125 - Delay to Diagnosis in Digestive Cancerology by the General Practitioner Related to Covid-19 Pandemic Confinement
Active, not recruiting NCT03678883 - 9-ING-41 in Patients With Advanced Cancers Phase 2